{
"id":"mk19_a_np_q034",
"number":34,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 34",
"stimulus":[
{
"type":"p",
"hlId":"a7ad9c",
"children":[
"A 62-year-old woman comes to the office for kidney transplantation evaluation. She has end-stage kidney disease. A peritoneal dialysis catheter was placed 2 weeks ago. She also has hypertension. Medications are amlodipine, benazepril, furosemide, metoprolol, and sodium bicarbonate."
]
},
{
"type":"p",
"hlId":"4b3a7a",
"children":[
"On physical examination, vital signs are normal. A peritoneal dialysis catheter is present. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"a3a396",
"class":"cell text l",
"children":[
"Hepatitis B core antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"3a242b",
"class":"cell text l",
"children":[
"Hepatitis B surface antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2ff2e8",
"class":"cell text l",
"children":[
"Hepatitis B surface antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"74fe78",
"class":"cell text l",
"children":[
"Hepatitis C antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"216558",
"class":"cell text l",
"children":[
"Hepatitis C viral load"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"35fc69",
"class":"cell text l",
"children":[
"2.8 million IU/mL"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Avoid antiviral treatment and transplantation"
}
},
{
"letter":"B",
"text":{
"__html":"Begin entecavir"
}
},
{
"letter":"C",
"text":{
"__html":"Begin pegylated interferon and ribavirin"
}
},
{
"letter":"D",
"text":{
"__html":"Discuss hepatitis C virus treatment and timing"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"2b9a6d",
"children":[
"In patients with end-stage kidney disease, treatment for concurrent hepatitis C virus infection can be timed before kidney transplantation or after transplantation if receiving a hepatitis Câ€“infected donor kidney."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"c46607",
"children":[
"The most appropriate management is to discuss hepatitis C virus (HCV) treatment and timing (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). This patient has evidence of HCV infection and hepatitis B virus (HBV) immunity (negative hepatitis B surface antigen, positive hepatitis B surface antibody). Screening patients for both viruses on admission to a dialysis center is part of ongoing infection control surveillance within a dialysis center. Identification of infection is important because treatment can be offered. All patients with HCV infection should be considered for treatment unless there are significant life-limiting comorbidities. Treatment regimens for HCV infection include a combination of direct-acting antivirals, using different mechanisms to prevent viral reproduction. Regimens are chosen based on genotype, previous treatment experience and response, and fibrosis status. The timing of HCV treatment must be individualized in patients such as this one with end-stage kidney disease (ESKD) who are potential kidney transplant recipients. It is important to discuss treatment and treatment timing with this patient and the kidney transplant program. In patients with ESKD, treatment for concurrent HCV infection can be timed before kidney transplantation or after transplantation if receiving an HCV-infected donor kidney."
]
},
{
"type":"p",
"hlId":"d702d6",
"children":[
"Antiviral treatment is safe and generally well tolerated in patients with ESKD, and the presence of HCV infection is not a contraindication for kidney transplantation. Neither avoiding antiviral therapy nor transplantation is appropriate for this patient (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
")."
]
},
{
"type":"p",
"hlId":"d2cd6d",
"children":[
"First-line treatment for HBV infection is entecavir (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") or tenofovir. However, this patient is immune to hepatitis B, and treatment is not warranted."
]
},
{
"type":"p",
"hlId":"4bfb8c",
"children":[
"Pegylated interferon and ribavirin (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") would not be indicated for this patient before a discussion about the timing of HCV therapy. In addition, many direct-acting antiviral regimens are available and are safe for use in patients with chronic kidney disease or ESKD with significantly less morbidity compared with interferon therapy."
]
}
],
"relatedSection":"mk19_a_np_s12_9_2_4_6",
"objective":{
"__html":"Manage hepatitis C virus infection in a patient with end-stage kidney disease."
},
"references":[
[
"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl (2011). 2018;8:91-165. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30675443",
"target":"_blank"
},
"children":[
"PMID: 30675443"
]
},
" doi:10.1016/j.kisu.2018.06.001"
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":0,
"B":4,
"C":7,
"D":89,
"E":0
},
"hlIds":[
"a7ad9c",
"4b3a7a",
"a462a3",
"a3a396",
"328929",
"3a242b",
"328929",
"2ff2e8",
"ffb935",
"74fe78",
"328929",
"216558",
"35fc69",
"cb2b54",
"2b9a6d",
"c46607",
"d702d6",
"d2cd6d",
"4bfb8c"
]
}